Maistering B.V & Mesterbakeren AS Sign a 5-year Digital Transformation Deal
28.1.2021 10:00:00 EET | Business Wire | Press release
Maistering, a global provider of an AI-infused business orchestration platform, today announced a strategic 5-year digital partnership with Mesterbakeren™.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210127006094/en/
Mesterbakeren™, headquartered in Oslo, Norway are the leading bakers offering the best in bread and bakery products to over 600 stores all over Norway.
As part of this engagement, Maistering, through its artificial intelligence platform, Master Collections, will deliver a complete 360° business view through enhanced collaboration with Mesterbakeren’s factories, partners and retail stores. The new platform augments leadership and teams with digital grip through AI-infused engines for insight, collaboration, creation, execution and governance.
Master Collections by Maistering is curated to enrich and speed up transformation initiatives. It allows leaders to plot and execute magical business journeys on the fly to improve, transform and innovate. The platform supports a fully virtual organization in a post-Covid world.
“Master Collections is a unique platform that helps enterprises orchestrate Journeys to reinvent themselves and shape value for customers, staff and partners. It will put AI-rich services and deep content at the fingertips of the Mesterbakeren™ team,” said Maistering CEO, John Brahim.
“After a two-month pilot with Maistering, we were convinced that Master Collections is the right platform for our digital transformation in our entire business from bakeries to customers. With Master Collections we radically shortened the introduction of a new product quality process. Our mission to be the leading bakery in Norway, inspiring, simple and best in taste, will be reinforced by going digital with Maistering,” added Tor Søreide Sivertsen, CEO of Mesterbakeren AS.
About Maistering B.V
Maistering is a global provider of an Enterprise SaaS business orchestration platform. An innovator that nurtures the innocence and energy of a millennial start-up with the deep, proven experience of business insights veterans. Headquartered in The Netherlands and supported by the uniquely designed CXO lab in Amsterdam, an AI hotspot, Maistering R&D sites are located in Bangalore (India), Rotterdam (Netherlands) and Valencia (Spain).
For additional information, please visit https://www.maistering.com/
About Mesterbakeren AS
Mesterbakeren™ delivers fresh baked goods to REMA 1000 in Norway. 20 bakeries supply retail stores all over the country with fresh bread, buns and rolls every day. The company targets to offer the best quality to Norwegian consumers, without costing more.
For additional information, please visit https://www.mesterbakeren.no/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210127006094/en/
Contact information
Maistering B.V
Vinutha Naik
Marketing Director
Vinutha.naik@maistering.com
Mesterbakeren AS
Steinar Bøe
IT Manager
steinar.boe@mesterbakeren.no
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f
Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 15:00:00 EET | Press release
Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end workflows spanning onboarding, KYC, AML, fraud, underwriting, payments, disputes, servicing, and collections. For
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom